SANJIVANI PARANTERAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224.8 INR | +2.67% |
|
+10.25% | +24.79% |
| Jun. 21 | Sanjivani Paranteral Limited Appoints Abhay Milan Shah as Independent Director | CI |
| May. 13 | Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| Sales 2022 | 306M 3.67M | Sales 2023 | 355M 4.25M | Capitalization | 414M 4.96M |
|---|---|---|---|---|---|
| Net income 2022 | 48M 575K | Net income 2023 | 45M 539K | EV / Sales 2022 | 2.32 x |
| Net Debt 2022 | 56.54M 677K | Net Debt 2023 | 21.91M 262K | EV / Sales 2023 | 1.23 x |
| P/E ratio 2022 |
13.5
x | P/E ratio 2023 |
9.19
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 38.83% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.67% | ||
| 1 week | +10.25% | ||
| Current month | +10.25% | ||
| 1 month | +30.97% | ||
| 3 months | +48.06% | ||
| 6 months | +27.84% | ||
| Current year | +24.79% |
1 week
201.00
232.85
1 month
167.25232.85
Current year
122.15232.85
1 year
62.00232.85
3 years
19.95232.85
5 years
5.66232.85
10 years
3.17232.85
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 96-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 96-12-31 | |
| Director/Board Member | 55 | 15-03-30 | |
| Director/Board Member | 50 | 22-03-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 224.8 | +2.67% | 27,912 |
| 24-07-04 | 218.9 | -1.82% | 22,796 |
| 24-07-03 | 223 | +2.13% | 24,797 |
| 24-07-02 | 218.3 | +4.98% | 101,907 |
| 24-07-01 | 208 | +2.01% | 27,691 |
Delayed Quote Bombay S.E., July 05, 2024 at 06:01 am EDT
More quotes
Sanjivani Paranteral Limited is engaged in the business of manufacturing pharmaceutical products. Its product category includes antibiotic, anti-emetic, non-steroidal anti-inflammatory drugs (NSAID) and analgesic, antimalarial, calcium and vitamin, sedative, steroid, cardiovascular, anti-fibrinolytic, anti-coagulant, vasoconstrictor, inotropic agent, anti-spasmodic, multivitamin, nutrition, iron, NSAID and analgesic, analgesic anti spasmodic, analgesic, and NSAID. Its antibiotic includes Netilmicin Sulphate, Amikacin Sulphate, and Gentamycin Sulphate. Its anti-emetic includes Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. Its NSAID and analgesic includes Acetaminophen Injection and Diclofenac Sodium Injection. Its calcium and vitamin include Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml. Its sedative includes Midazolam Hydrochloride, Diazepam, and Dobutamine Hydrochloride. Its Iron includes iron Sucrose. Its analgesic includes Metamizole.
Sector
Pharmaceuticals
Calendar
2024-07-21
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +24.79% | 31.45M | |
| +56.89% | 823B | |
| +39.52% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +13.74% | 239B | |
| +13.83% | 220B | |
| -0.49% | 219B | |
| +7.94% | 167B |
- Stock Market
- Equities
- SANJIVIN Stock
